Delcath Systems (NASDAQ:DCTH – Get Free Report) released its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19, RTT News reports. The business had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. During the same quarter in the prior year, the company posted ($0.86) earnings per share.
Delcath Systems Stock Performance
NASDAQ DCTH opened at $5.09 on Thursday. Delcath Systems has a 52-week low of $2.25 and a 52-week high of $7.99. The firm has a 50-day moving average of $4.34 and a 200-day moving average of $3.84. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.11 and a current ratio of 3.30.
Insider Buying and Selling at Delcath Systems
In other news, Director Gil Aharon acquired 26,882 shares of Delcath Systems stock in a transaction dated Tuesday, March 19th. The stock was bought at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now directly owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 21.10% of the company’s stock.
Hedge Funds Weigh In On Delcath Systems
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the company. StockNews.com raised Delcath Systems to a “sell” rating in a report on Wednesday. HC Wainwright boosted their price objective on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.50.
Check Out Our Latest Analysis on DCTH
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Further Reading
- Five stocks we like better than Delcath Systems
- What Makes a Stock a Good Dividend Stock?
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- 3 Fintech Stocks With Good 2021 Prospects
- Cintas or UniFirst: Investors Win Either Way
- What Are Dividend Challengers?
- Best Bear Market Funds: Top 3 Investment Options to Consider
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.